Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens-Reference-Cited by-同舟云学术

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Published:2020-02-11 Issue:6 Volume:22 Page:938-946
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Frias Juan Pablo¹^ORCID,Nauck Michael A.²^ORCID,Van Joanna³,Benson Charles⁴,Bray Ross⁴,Cui Xuewei⁴,Milicevic Zvonko⁵^ORCID,Urva Shweta⁴,Haupt Axel⁴^ORCID,Robins Deborah A.⁴^ORCID

Affiliation:

1. National Research Institute Los Angeles California United States

2. Diabetes Center Bochum‐Hattingen, St Josef Hospital, Ruhr‐University Bochum Bochum Germany

3. Diabetes Research Center Tustin California

4. Eli Lilly and Company Indianapolis Indiana

5. Eli Lilly and Company Vienna Austria

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine